6 Best Continuous Glucose Monitors for 2026: Most Accurate and Latest Devices Reviewed

Editor’s Note: T1D Strong regularly updates articles to reflect the latest developments and resources for people with type 1 diabetes. As always, it’s important to discuss medical decisions with your healthcare provider, especially when you receive safety notices and recalls.

If you’re newly diagnosed with type 1 diabetes (T1D), chances are that you’ve learned a great deal of diabetes-related technology terminology in a short window.  A diagnosis brings a steep learning curve, followed by important decisions about which blood glucose meter (BGM), insulin pen, insulin pump, or continuous glucose monitor to purchase.

Hopefully, you have an excellent physician and healthcare team to weigh all the options with you.

If you have the luxury of choosing a continuous glucose monitoring system, it provides a safety net against extremely low and high blood glucose levels. According to the American Diabetes Association (ADA), individuals wearing CGMs significantly benefit from higher time in range (TIR)—typically 70–180 mg/dL—and improved daily energy and sleep, as well as reduced hypoglycemic events and long-term complication risk.

Notably, MARD (Mean Absolute Relative Difference) scoring is the standard way to measure CGM accuracy. For example, the Dexcom G7 claims an 8.2% for adults and 8.1% for children, and the G6 has a MARD of 9% for adults inserted into the stomach. The smaller the MARD score, the closer the CGM readings are to the actual glucose value, whereas a larger MARD score indicates greater discrepancies. Most systems have an average MARD of 9-14%.

What is a Continuous Glucose Monitor (CGM)?

CGMs are wearable diabetes tech used to help manage blood glucose levels. The small device has a tiny needle (sensor) worn under the skin that sends a signal to a transmitter/smartphone, which displays the results.

Individuals can attach the sensor to their arms, upper buttocks, thighs, or stomach, where it automatically estimates their blood sugar level.

This real-time facet of CGMs is impressive, with calculations and calibrations improving since its inception.

Most health insurance plans now cover CGMs, but you'll need a prescription. A few exceptions include Dexcom's new Stelo Glucose Biosensor System, which can be purchased over-the-counter (OTC). Additionally, Abbott's Lingo (for metabolic health) and Libre Rio (for type 2 diabetes, non-insulin) are also recently OTC options.

Interesting Fact: Abbott is developing a new biowearable sensor that monitors both blood glucose and ketone levels in real time.

Here's T1D Strong's Quick List: Best CGMs for 2026

1. Dexcom G7 – Best overall for accuracy and ease of use
2. Abbott FreeStyle Libre 3 Plus  - World's smallest and thinnest CGM
3. Eversense 365 – First long-term implantable CGM (365 days)
4. ‍Medtronic Guardian 4 - A calibration-free CGM for pump users
5. Medtronic Instinct– A compact CGM with 15-day wear for pump users‍
6. Dexcom Stelo – First over-the-counter CGM for type 2 diabetes

1. Dexcom G7 (Best over all for most users)

• Wear time: 15.5 days
• Accuracy: MARD 8.2% (adults), 8.1% (children), and 7.7% for ages 2 to 6.
• Best for: People who want a fast warm-up, long wear-time, small size, and smartwatch compatibility

The Dexcom G7, released in early 2023, has many updated features compared to the Dexcom G6. Most notable is the size; the G7 is 60% smaller than the G6, with a more circular shape, similar to the Freestyle Libre 3 Plus. Being smaller, it’s more comfortable and less intrusive. The waterproof device is widely regarded as the best overall because of its high accuracy, fast warm-up time (30 minutes compared to the G6’s two hours), and excellent app/smartwatch integration.

Most importantly, the Dexcom G7 now offers 15.5 days of wear (including a 12-hour grace period), up from the standard 10.5-day wear time of the original G7.

Another benefit of the G7, in addition to its shorter warm-up time, is its one-step application process. In contrast, the G6 has a two-step process and requires a separate transmitter.

Currently, the G6 offers broader insulin pump integration than the 67, though this is changing with wider compatible connectivity rolling out gradually.

• Dexcom G6: Compatible with Tandem t:slim X2, Tandem Mobi, Omnipod 5, Omnipod DASH, and the iLet Bionic Pancreas
• Dexcom G7: Integrates with Tandem Mobi and t:slim X2, the Omnipod 5, with other integrations in progress

Important Fact: In 2025, the FDA issued recalls for certain Dexcom G7 receivers, but the company addressed the issues, recalled the affected devices and confirmed the manufacturing problems had been resolved. In 2026, the G7 system remains FDA-cleared and widely available.

2. Abbott FreeStyle Libre 3 Plus (Smallest, most discreet sensor with real-time data)

• Wear time: 15 days (with no warmup)
• Accuracy: MARD ~8.2% (Studies show Libre 3 and Dexcom G7 are very close in comparison)
• Best for: Affordability, people who want continuous real-time data and very small sensors. ‍
• Suitable for children 2 years and older.

The Abbott FreeStyle Libre 3 Plus is a real-time CGM system, meaning it continuously sends glucose readings (every minute) to your smartphone via Bluetooth. It’s the world’s smallest and thinnest sensor (the size of two stacked pennies), and features enhanced connectivity, with a long-range Bluetooth connection (up to 33 feet). 

The Libre 3 Plus works with several automated insulin delivery (AID) systems: Tandem: t:slim, Omnipod 5, iLet Bionic Pancreas, and Twiist. It’s water-resistant, withstanding immersion in up to three feet of water for up to 30 minutes.

Device use is approved only on the back of the arm, not the stomach. The FreeStyle Libre is compatible with both iOS and Android Phones, and the application is easy to use on both.

Important Fact: The FDA issued recalls for certain Abbott FreeStyle Libre 3 and Libre 3 Plus sensors. Abbott identified and resolved a manufacturing issue, resulting in a Medical Device Correction in late 2025. Consumers can visit www.FreeStyleCheck.com to check whether their sensors are affected and to get a replacement at no charge.

3. Eversense® 365

• Wear time: 365 days (1 year, implantable)
• Accuracy: MARD 8.8%‍
• Best for: Adults seeking long-term wear, on-body vibration alerts, and fewer sensor changes

Ascensia Diabetes Care recently launched Eversense 365, a one-year implantable CGM for adults with diabetes. As the only CGM with a removable transmitter that can be easily taken on and off without wasting a CGM or adding a warm-up period, Eversense® 365 requires only a single warm-up period each year. 

Following the recent FDA approval, this new development is transforming diabetes management, as Eversense is now the World’s First One-Year CGM. One implanted sensor provides long-term, year-round use, compared with 10-14 days of short-term CGM service.

‍Eversense 365 reduces the burden of data interruption and sensor failures. Other benefits include more freedom, comfort, improved discretion, and on-body vibration alerts that notify patients even when their mobile phone is out of sight.

The Eversense 365 Continuous Glucose Monitoring system boasts an impressive (MARD) of 8.8%, indicating high accuracy in glucose measurements.

However, currently, the Eversense 365 is FDA-approved only for adults aged 18 and older. While the company has initiated clinical trials involving pediatric participants, the device is not yet approved for use in children.

Additionally, Medtronic now offers three primary CGM sensors—the Guardian 4, Simplera Sync, and Instinct—to provide users of their MiniMed™ 780G system with more choices, improved comfort, and increased reliability in their automated insulin delivery. Medtronic is not phasing out one for the other, but expanding its portfolio.

Important to note that both the Guardian 4 and Instinct sensors are designed to work exclusively with the MiniMed 780G insulin pump system from Medtronic, enabling its automated insulin delivery features and SmartGuard technology.

4. Medtronic Guardian™ 4 (Calibration-free CGM that delivers real-time data)

• Wear time: The Guardian 4 lasts seven days‍ with two hour warm up, and the new Instinct lasts 15 days with a one-hour warm-up
• Accuracy: Studies report the MARD range is between 8.2% and 10.6%‍
• Best for: People using Medtronic insulin pumps, ages seven and up

The established, reliable sensor checks glucose levels every five minutes, providing a constant stream of data to help users stay informed with trends throughout the day and night. When paired with Medtronic’s MiniMed 780G insulin pump and SmartGuard™ technology, it stands out for its calibration-free operation, seamless integration, and a consistently reliable seven-day wear time on the abdomen, upper arm and buttocks. 

While the Guardian 4 remains available for use with the MiniMed 780G system, in late 2025, Medtronic began selling its new CGM, Instinct, made by Abbott. The new systems also offer real-time glucose monitoring and automatically adjust insulin. Instinct is a much smaller device and offers double the wear time.

5. Medtronic Instinct (Continuous real-time CGM with 15-day wear)

Medtronic's newest sensor, manufactured by Abbott was launched in September 2025 and requires no calibration. It's Medtronic's smallest sensor, offering 15 days of wear with a one-hour warm-up. It's water-resistant for up to three feet for 30 minutes. Its sleek design has a very simple insertion process.

Both systems are used with the Minimed Mobile app. Interesting to note, though it is not yet approved by the FDA, Medtronic's next-generation InPen with Instinct (MiniMed Go) is for users not ready for the AID system. It offers smart-dosing technology through its own app.

Metronic Tip: For the best connection, it's advised to wear the Instinct CGM and 780G system pump on the same side of your body.

Medtronic's Simplera Sync

Significantly, Medtronic's Simplera Sync is a fully disposable, all-in-one glucose sensor that doesn’t require overtape and features an easier two-step insertion process. The Simplera Sync, when paired with the MiniMed 780G insulin pump or the InPen, provides glucose readings every five minutes, using its SmartGuard Technology to predict, adjust and correct glucose levels day and night. Calibrations are not required with the Simpera Sync either.

The Simplera Sync is for users aged 7 and up, and it lasts up to 6 days, with a 24-hour grace period and a 2-hour warm-up. Simplera use with the InPen is ages 18 and up.

6. Dexcom Stelo (OTC, Type 2 focused)

• Wear time: 15 days
• Accuracy: Built on G7 platform, similar performance (around 8–9% MARD)‍
• Best for: Adults with type 2 diabetes who are not insulin-dependent and want an over-the-counter CGM

Dexcom’s new Stelo is the first FDA-approved glucose biosensor designed for people living with type 2 diabetes (T2D), and the first OTC CGM available without a prescription. Stelo is built on the same Dexcom G7 platform, but it’s intended for a T2D patients and is manufactured with different software and a user experience tailored to this audience.

Stelo users are typically individuals who aren’t insulin dependent. The G7 has alerts for low blood glucose levels for insulin users, while the Stelo sends phone alerts for glucose spikes.

The Stelo app focuses on real-time insights and glucose trends, while the G7 is laser-focused on low blood sugar alerts. The sensor warm-up/calibration period is approximately the same as the G7, with a 30-minute warm-up time.

Should I Get a CGM?

The recommendations for acquiring a continuous glucose monitor are increasingly favorable. The American Diabetes Association, Breakthrough T1D (formerly JDRF), the National Institutes of Health (NIH), and the Endocrine Society all say CGMs help individuals with type 1 and type 2 achieve their glycemic targets.

Doctors especially advocate CGMs for people with problematic hypoglycemia and hypoglycemic unawareness, which occurs when an individual doesn't feel a low blood glucose episode. Hypoglycemic unawareness affects about 40% of people with type 1 diabetes.

When choosing a CGM, you must consider many factors besides its unique bells and whistles: price, ease of use, connectivity, accuracy, and data management.

Bottom Line: CGMs are a Life-Saving Technology

If you are fortunate enough to try a CGM system, these AI-tracking devices are the future of diabetes care. Glucose meters and syringes may one day be a thing of the past. Just as smartphone apps and smart devices are a part of everyday life, diabetes technology is growing exponentially to the point where commercial insurance companies will be forced to cover most individuals.

The CGM sensors keep getting smaller, they provide excellent target range, and the devices make it easier for patients to participate in clinical trials. CGM systems allow T1D individuals increased wearability and reliability by adding the freedom to pursue intense physical activity and lengthy outdoor adventures.

CGMs allow T1Ds control over their condition with continuous feedback. If you want to participate in your diabetes care proactively and can afford one, CGMs stand out. They help you make informative decisions based on actual statistics and can be a game changer for improving your hemoglobin A1c level and overall health.